Retinalamin

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

Retinalamin is not FDA-approved for any indication, has no USP/NF monograph, and does not appear on FDA's 503A or 503B bulk drug substance lists. It was not among the peptides addressed by the April 2026 FDA/HHS Category-2 reclassification (docket FDA-2025-N-6895; PCAC review July 23-24, 2026). Sale or supply for human use in the US is not authorized; it is available, if at all, only as a research-use-only laboratory material.

No verifiable third-party COA path in this market

Transparent blend · bci-1.0 · never paid-placement

Primary name

Retinalamin

Origin

Retinalamin is a standardized complex of water-soluble polypeptide fractions extracted from cattle (bovine) retina, developed within the Russian peptide-bioregulator research tradition associated with Vladimir Khavinson and colleagues and manufactured/marketed in Russia by Geropharm. It is registered there as a prescription ophthalmic drug administered by parabulbar, retrobulbar, subconjunctival, or intramuscular injection, typically in short courses. Like Cerebrolysin (brain-derived), it is a defined mixture of peptide fractions rather than a single characterized molecule, and no PubChem, UniProt, or comparable single-entity registry record exists for it (see overrides/identity.json).

Appearance

Lyophilized powder for reconstitution (vendor/product-typical for the Geropharm ophthalmic product; 5 mg per vial in the clinical studies cited)

Solubility

Water-soluble polypeptide fractions; reconstituted in saline or water for inject…

Sequence not available in current seed.

Stability: As an undefined mixture of peptide fractions, stability data specific to Retinalamin were not identified in the peer-reviewed literature reviewed; handle per ge

Vial sizes

5 mg

Purity grades

research grade

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• An in vitro/in vivo mechanistic study (PMID 34726863) using competitive radioligand binding found that the retinal polypeptide preparation interacts with several glutamate receptor subtypes (AMPA, NMDA, mGluR1) associated with retinal ganglion cell loss, and demonstrated biodistribution to eye and brain tissue after intravenous, intramuscular, and parabulbar administration in mice (tissue levels assessed at a 1.7 mg/kg dose), with renal excretion suggested as the main clearance route
• Based on this glutamate-receptor interaction, the proposed rationale is neuroprotection against excitotoxic retinal ganglion cell injury — a mechanism relevant to glaucoma and diabetic retinal neurodegeneration
• However, a separate controlled preclinical study in an experimental model of photochemical retinal damage in rabbits (PMID 34726859, parabulbar 0.25 mg/kg x 10 days) found NO statistically significant functional (electroretinogram) or morphological (histology/TUNEL apoptosis) evidence of a neuroprotective effect versus vehicle control, so the preclinical picture is mixed rather than uniformly supportive

Pharmacokinetics (ADME)

Half-life

No formal peer-reviewed human pharmacokinetic study identified; the compound is a peptide-fraction mixture rather than a single defined molecule, which itself complicates conventional single-analyte PK characterization.

Clearance

A mouse biodistribution study (PMID 34726863) suggests renal excretion as the principal route; not established in humans.

PK–PD note: The same biodistribution study reported measurable drug levels in eye and brain tissue within 0.5 hours of intravenous or intramuscular administration at 1.7 mg/kg in mice — this is animal biodistribu…

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Erichev et al. 2020 — 'Peptide bioregulators: delivery and efficacy' (Vestn Oftalmol) — Narrative review of Khavinson-class peptide bioregulators incl. Retinalamin; closest analogue to a review anchor — NOT a formal systematic review.
• Khavinson et al. 2013 — 'Peptide bioregulators: the new class of geroprotectors. Message 2' (Advances in Gerontology) — Narrative review synthesizing the authors' own prior clinical observations; does NOT present a specific RCT with a patient count.
• Gabdrakhmanova et al. 2018 — neuroretinoprotection in primary open-angle glaucoma (Vestn Oftalmol) — Mechanistic review of the antioxidant / retinoprotective rationale for polypeptide bioregulator therapy in glaucoma.

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No peer-reviewed data from independent Western research groups characterizing systemic safety, drug interactions, carcinogenicity, or use in pregnancy/lactation were identified. The Russian clinical literature surveyed here does not report serious adverse events attributable to R…

WADA status

Not specifically named on the WADA Prohibited List. Retinalamin has no established growth-factor, hormonal, or performance-enhancing mechanism in the literature…

Dominant research route: Retinalamin is a registered Russian drug (not a self-administered research peptide in its home literature), dosed exclusively by clinician-administered injection. The two documented routes are intramuscular (systemic) and parabulbar/retrobulbar injection into the periocular tissue (local/regional). The manufacturer instructions state it is 'intended exclusively for injection: intramuscular or parabulbar' and warn it is NOT for self-administration.

Registered-label route in Russian clinical use and an arm of a published human comparative study (Erichev et al., Vestn Oftalmol 2020;136(2):56-62, PMID 32366071; 498 eyes with open-angle glaucoma at compensated IOP; combined IM+retrobulbar n=110, retrobulbar-only n=171, IM-only arm). Human only; no animal PK study located.

Bioavailability: No formal PK (Tmax/half-life/absolute bioavailability) parameters located. Per the manufacturer (Geropharm) package insert AS REPRODUCED BY vendor product pages (Layer B paraphrase, NOT an FDA/regulatory label): the 5 mg lyophilisate is reconstituted in 1-2 mL water for injection, 0.9% saline, or 0.5% procaine, once daily at 5-10 mg for a 5-10 day course. In the comparative study the three routes were reported as having COMPARABLE efficacy for initial/moderate-stage glaucoma (attributed study finding, not a durable-efficacy or dosing recommendation). [Corrected: a first-pass '~1 cm parabulbar injection depth' figure was DROPPED — it is not on any cited page or manufacturer instruction.]

A clinician-administered registered-label route, documented in the Layer-A PMID 32366071 study; not a self-administration route. Reported as the studied administration method, never a human-dosing recommendation.

The primary route on the Russian product label (parabulbar — injection into the tissue surrounding the eyeball, via the upper-eyelid skin) and the route used as 'retrobulbar' in the human comparative glaucoma study (Vestn Oftalmol 2020;136(2):56-62, PMID 32366071) alongside/against the IM route. Human only. [Corrected: the first-pass '~1 cm injection depth' figure was dropped as uncorroborated.]

Bioavailability: No formal systemic-bioavailability figure is published; this is a local/regional periocular injection intended to deliver the peptide adjacent to the eye. Per the Geropharm insert as reproduced by vendor pages (Layer B paraphrase): 5-10 mg once daily (diabetic retinopathy / retinal dystrophy) or 5 mg once daily (glaucoma, myopia) for 5-10 or 10-day courses, reconstituted as for the IM route. The comparative study found retrobulbar-only, IM-only and combined administration COMPARABLE in initial/moderate-stage glaucoma (attributed finding; some functional gains at 3 months partly regressed by 6 months).

Clinician-administered periocular injection; label/vendor safety notes warn it may cause temporary visual blurring (avoid driving until vision clears) and is explicitly not a self-administration route. 'Parabulbar' (label) and 'retrobulbar' (study) are related but technically distinct periocular techniques used somewhat interchangeably across sources. Reported as studied administration, not a human-dosing recommendation.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Researched storefront prices, bucketed

p25 $2.31 · median $4.60 · p75 $10.44 · 11 researched vendors

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$23

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

No independent third-party lab aggregate (Janoshik, Finnrick, MZ Biolabs) publishing Retinalamin-specific purity data was found — see underdosingNote. A couple of US research-chem vendors advertise a self-reported purity spec on their own pages (e.g. Iron Mountain Labz lists '>98%'), but these are unverified vendor marketing claims with no linked product-specific COA, not independently confirmed lab results.

Independent labs cited for this compound

No Retinalamin-specific FDA enforcement action, recall, warning letter, or DOJ case was found as of 2026-07-16 — an honest empty result, confirmed against QUERYABLE PRIMARY DATABASES (openFDA drug + device enforcement APIs return 0 matches on product_description/reason_for_recall; the Federal Register API returns 0 documents), not merely a generic landing page. Context: Retinalamin IS a registered Russian prescription drug (GEROPHARM) but has no FDA approval/evaluation; in the US it is sold only under 'research use only' labeling outside the regulated channel — a thinner enforcement profile than higher-volume peptides like BPC-157. Absence is bounded to 'no action found in FDA/DOJ/Federal Register primary sources as of the check date', not an affirmative regulatory clearance.

Buyer red-flag checklist

• SUBSTANCE-IDENTITY MISMATCH: US 'USA-made' storefronts (Iron Mountain Labz, PureRawz) sell a vial labeled 'Retinalamin'/'Retilanamin' tagged with CAS 17105-15-6 / C11H21N3O5, which resolves in PubChem (CID 7015685) to epsilon-(gamma-glutamyl)-lysine (a transglutaminase-crosslink dipeptide) — an entirely different substance from the genuine GEROPHARM multi-fraction bovine-retina polypeptide mixture (no PubChem/UniProt record). The US research-chem vials should not be assumed to be the registered drug absent a lab COA.
• Category grey-market sourcing risk: reporting (Futurism, 'eBay Is Selling a Cornucopia of Russian Peptides', 2026, Layer B, category-level — not a Retinalamin-specific incident) describes Russian-origin peptide bioregulators from the same St. Petersburg/Khavinson family being resold with 'murky provenance' and no regulatory oversight.
• No batch-specific COA provided on request — a general research-peptide red flag, doubly relevant here given the near-total absence of independent lab coverage for this compound.
• Vendor purity claim (e.g. '>98%') with no linked, verifiable third-party lab report.
• COA report/task ID that does not resolve in the issuing lab's public verification database (fabricated or edited certificate).
• Product sourced/relabeled from an unverified Russian/CIS distributor rather than the registered manufacturer (GEROPHARM) or an authorized reseller.
• Human-dosing or clinical-benefit marketing copy on a site labeling the product 'research use only' — the pattern that draws FDA warning letters.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent underdosing/mislabeling prevalence study covering Retinalamin was found. Cross-checked against the two main public independent-lab datasets used elsewhere on this platform: (1) Janoshik Analytical's public peptide catalog carries named pages for dozens of common research peptides but no Retinalamin listing; (2) the MZ Biolabs 10-sample investigation (thepeptidelist.com, Jan 2026) tested BPC-157, Semaglutide, CJC-1295 and GHK-Cu — Retinalamin was NOT among them. Finnrick shows no Retinalamin product page. This is a genuine testing-coverage gap (a niche, low-volume compound outside the mainstream independent-lab sample), not evidence of either purity or contamination, and must not be read as a clean-market signal.

• No Retinalamin-specific FDA import alert was found. FDA Import Alert 66-41 ('Detention Without Physical Examination of Unapproved New Drugs Promoted In The U.S.') authorizes DWPE only for firms/products on its Red List (which includes certain named peptides tied to specific firms, e.g. bremelanotide/PT-141, dermorphin) — it does NOT automatically cover all unapproved peptides, and Retinalamin is not a listed entry. As an unapproved-in-the-US drug marketed 'research use only', an individual Retinalamin import shipment could still be refused under FD&C Act sec. 801(a)/505 as an apparent unapproved new drug; that statutory exposure must NOT be stated as coverage by, or a listing under, Import Alert 66-41.No Retinalamin-named import alert; IA 66-41 does NOT apply generically
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically named on the WADA Prohibited List, the USADA substances database, or Global DRO (checked 2026-07-16). IMPORTANT CAVEAT: the WADA list defines prohibited substances by CATEGORY (S0, S1, S2, …), not by product/brand name, so absence of a by-name listing does NOT mean the substance is permitted in sport. As a polypeptide preparation not approved for human use by any major regulator, Retinalamin could fall under S0 (substances not approved by any governmental regulatory authority) or, depending on composition, S2 (peptide hormones/growth factors). Not personalized anti-doping guidance — athletes should verify current status via Global DRO or their anti-doping organization. This is an absence-of-listing finding, not a from-source WADA statement about this specific compound.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Extremely thin discourse volume for this exact compound — across many query variations, no Reddit, YouTube, Bluesky, or X thread specifically naming 'Retinalamin' could be confirmed this pass; platforms[] is left empty.
• The two identifiable forum threads that mention Retinalamin by name (GLP-1 Forum, LongeCity 'Peptide Bioregulators (Russian)') are neither Reddit/YouTube/Bluesky/X; they informed the theme framing but are excluded from platforms[], and sampleAuthorMass is scaled to illustrative single digits.
• Vendor/blog and YouTube content for this product family is dominated by 'Visoluten' (the Khavinson A-11 capsule sold to Western audiences), a different, related-but-distinct product — excluded here, not merged in.
• Search-engine indexing of Reddit under-surfaces niche/older threads; absence from these results is 'not confirmed this pass', not proof of zero organic discussion.
• Available English-language content is overwhelmingly reseller/pharmacy product pages rather than peer-to-peer experience reports, skewing the little available text toward clinical/marketing framing.
• GEROPHARM self-reports anti-counterfeit packaging (barcode + perforated first-opening flap) on its product page — a manufacturer-side signal that protection against counterfeit product is designed-for. This does NOT document any specific counterfeiting incident or 'relabeling' in the channel; no Retinalamin-specific 'I received a fake' report was found this pass.

Manually researched from — theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Russian-registered retina-derived polypeptide bioregulator (Geropharm) studied by parabulbar/retrobulbar/intramuscular injection as adjunct neuroprotective therapy in glaucoma and diabetic retinopathy; part of the Khavinson-group Cytamins/Cytogens bioregulator family alongside Cerebrolysin, Cortexin, and Thymalin. Approximately 23 articles are indexed (literature last scanned 2026-07-16). US regulatory status: Research Use Only — no lawful compounding or marketing pathway. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet